Business Wire

Phenom Recognized as a Strategic Leader in Fosway’s 2022 9-Grid™ for Talent Acquisition for Second Consecutive Year

4.5.2022 16:36:00 EEST | Business Wire | Press release

Share

Phenom, the leading AI-powered talent experience platform, has been named a Strategic Leader in the 2022 Fosway 9-Grid™ for Talent Acquisition for the second year in a row. Fosway identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to consistently meet the needs of complex enterprise-scale customers. According to Fosway, Phenom has proven its ability to deliver higher levels of innovation, customer impact and advocacy compared to alternatives in the market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220503006092/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Phenom positioned as Strategic Leader in Fosway 9-Grid (Graphic: Business Wire)

With the highest job vacancy rate Europe has seen in 14 years, the talent shortage has developed into a crisis that extends far beyond human resources. To better connect with candidates and quickly fill open roles, CHROs and CEOs from today’s leading enterprises are choosing systems of intelligence to automate tasks and provide personalised experiences that job seekers expect in today’s competitive talent market.

Phenom’s position as a Strategic Leader reinforces that its Talent Experience Management (TXM) platform is enabling enterprises with the AI and automation necessary to quickly identify and hire best-fit talent, and an intelligent talent marketplace to develop and retain their best employees.

“Organisations are facing acute recruitment challenges that require innovative approaches to talent acquisition," said David Wilson, CEO, Fosway Group. "Phenom has consolidated its position as a Strategic Leader on the 2022 Fosway 9-Grid™ for Talent Acquisition through its focus on innovation and harnessing talent intelligence to deliver better recruitment outcomes for customers."

In 2021, 50,000 recruiters, talent marketers and hiring managers used Phenom to hire over 2 million people and engage over 5 million employees. Built on a vast network of data, contextual industry models and deep learning, the Phenom TXM platform is empowering organisations to:

  • Engage & hire best-fit candidates faster: Connecting job seekers with relevant job recommendations and content based on skills, experience and location with a personalised Career Site, conversational Chatbot and CMS.
  • Improve recruiter productivity: Identifying best-fit talent for open roles and automating tedious administrative tasks with a talent CRM, Campaigns, AI Scheduling, Video Assessments and AI Insights.
  • Develop and retain employees: Fostering employee engagement, growth, and retention with an Internal Talent Marketplace, Career Pathing, Internal Mobility, Gigs, Diversity, Equity & Inclusion and Employee Resource Groups.
  • Enable hiring managers: Streamlining collaboration with managers and elevating meaningful insights through talent analytics.

AXA, a global insurance company and Phenom customer, continues to see new value in the Phenom platform every day.

“With Phenom, it’s easier than ever for employees and candidates to explore open jobs across our organisation. Since the platform is constantly capturing and analyzing data, it’s delivering personalized experiences to help everyone find the right fit. When we’re able to connect people with opportunities where they can shape the way they work and realize their potential, that’s the greatest achievement of all,” said Amanda Vaughan, Global Head of Talent & Learning at AXA.

“As enterprises rely on talent experience to meet hiring demands in EMEA, maintaining our position as a Strategic Leader in Fosway’s Talent Acquisition grid signifies how we’re planting our roots in the HR technology market,” said Jeff Carey, senior vice president of international business at Phenom. “Our customers chose Phenom as the AI-powered solution to not only help them find candidates faster and retain talent today — they’re also investing in our constant innovation to ensure they’re future-proofed for the inevitable demands that will arise tomorrow.”

Companies across EMEA are successfully adopting Phenom’s talent experience platform to help candidates find the right job faster, recruiters discover best-fit talent, employees learn and evolve and managers build their teams. To support the growing need for Talent Experience Management, Phenom acquired three Europe-based companies and now has employees based in countries including Germany, France, Ireland, the Netherlands, Switzerland, Italy, Spain and the United Kingdom.

To learn more about Phenom’s Strategic Leader position, please visit their blog.

To see Fosway’s full analysis, check out their 2022 9-grid™.

About Phenom

Phenom is a global HR technology company with a purpose to help a billion people find the right job. With an expertise in building AI-powered, scalable solutions, Phenom Talent Experience Management (TXM) personalises and automates the talent journey for candidates, recruiters, employees and managers with its Career Site, Chatbot, CRM, CMS, SMS and Email Campaigns, University Recruiting, Internal Mobility, Career Pathing, Diversity & Inclusion, Talent Marketplace, Gigs, Referrals, Hiring Manager and Analytics. As a result, employers improve their talent acquisition and talent management efforts by helping candidates find the right job, employees grow and evolve, recruiters discover top talent, and managers build teams faster. Phenom was a winner in the Business Intelligence Group’s 2021 Artificial Intelligence Excellence Awards program for its sophisticated machine learning capabilities and was ranked among the fastest-growing private companies in the 2021 Inc. 5000.

Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.

For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Jennifer Lyons
Director, Global Communications
267-379-5066
jennifer.lyons@phenompeople.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 10:00:00 EEST | Press release

Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use cases demonstrating how AI and advanced automation are helping operators address increasing network complexity, strengthen fraud prevention, improve service assurance, and drive operational efficiency. A central theme across

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release

Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release

Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye